Video

June 21, 2019

Dr Stephen Silberstein on How Patients Are Reacting to CGRP Inhibitors

Stephen Silberstein, MD, director of the Jefferson Headache Center, discusses patient reactions to being prescribed a CGRP inhibitor.

Transcript:

How have patients reacted to being prescribed [calcitonin gene-related peptide] CGRP inhibitors?

In contrast to what we believed, patients are calling and rushing into the office to get the CGRP drugs because they're safe, they're effective, [they have] minimal if any side effects, and they don't have to take a pill every day.

Related Content

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com

April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

April 16th 2025

Empowering Teams Begins With Human Connection: Missy Hopson, PhD

Kyle Munz Missy Hopson, PhD

Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

April 9th 2025

Addressing Unmet Needs, Emerging Treatment for Atopic Dermatitis: Raj Chovatiya, MD, PhD

Cameron Santoro Raj Chovatiya, MD, PhD, MSCI

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.

April 8th 2025

Coverage With Evidence Development Study Shows Benefits in Patients With Migraine Treated With Remote Electrical Neuromodulation

Andrea Synowiec, DO Alit Stark-Inbar, PhD Dolores Dominguez Santamaria, MD Matthew Fickie, MD Stephen Ross, MD

A coverage with evidence development (CED) study demonstrated significant and clinically meaningful benefits in patients with migraine treated with remote electrical neuromodulation (REN). Health plans should support clinicians’ REN prescriptions by ensuring adequate coverage.